Focused on Advancing the Flow of LifeAbout V-WAVE
V-WAVE was established in Israel in 2009 with a focus on developing percutaneous implantable technologies for patients with chronic heart failure. Technology designed by V-Wave, highlighted by its Ventura® Interatrial Shunt System, was designed to help heart failure patients with relief of symptoms, reduced hospitalizations, and improved quality of life.
V-Wave is a privately held company with offices in Caesarea, Israel and Agoura Hills, California.
This is a company that is built on science, engineering, and medicine. We are leveraging decades of experience in these fields to bring unique ideas and technologies to bring new therapy options to patients, including those suffering from heart failure and cardiovascular disease.
Our goal is to provide hope and relief for the millions who live with these diseases every day.
A Company Dedicated to Ideas That Change How We Treat Patients and Disease
See how we have built our team and its ideas from the start.
V-Wave was established in 2009 in Israel to develop interatrial shunt devices for patients suffering from chronic heart failure. The goal is to use the shunt to lower left atrial pressure (LAP) and thereby reduce symptoms and improve clinical outcomes. The initial concept focused on a device implanted with a minimally invasive catheter-based procedure that incorporated a novel hourglass design with venturi-like flow efficiency and a one-way tissue valve. The V-Wave shunt was first implanted in a heart failure patient in October 2013.
In 2015, well-known interventional cardiologists and serial medtech entrepreneurs, Neal Eigler, MD and Frank Litvack, MD, joined V-Wave as CEO and Board Chairperson, respectively.
In 2016 V-Wave shared results of its early experience in a multi-center study showing a very high rate of device implantation success, excellent safety, and relief of symptoms. The study gave insights for design improvements, including removal of the valve to achieve the most reliable and long lasting results.
In 2018, the company received regulatory approvals to perform a pivotal randomized, double-blinded, controlled clinical trial – RELIEVE-HF – to assess the safety and effectiveness of the V-Wave Ventura® Interatrial Shunt System in heart failure patients that remain symptomatic despite standard of care treatment. The study is ongoing with a target enrollment of 500 to 700 patients.
In 2020, V-Wave received CE Mark for the Ventura Interatrial Shunt System, allowing for eventual commercial use in Europe.
V-Wave is a privately held company, headquartered in Israel with offices in Southern California.
Meet the team behind our mission and our technology.
News and Events
Learn more about what is happening today at V-WAVE.